TRIAL DETAIL
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
Drug: |
||||
|---|---|---|---|---|
Trial Name: |
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy |
|||
NCT#: |
||||
Conditions: |
Gastrointestinal Stromal Tumor |
|||
Status: |
Not yet recruiting |
|||
Phase: |
3 |
Start Date 12/05/2025 |
Age of Trial (yrs) 0 |
|
Treatment Phase: |
Gleevec-resistant |
|||
Drug Category: |
KIT/PDGFRA inhibitor |
|||
Strategy: |
Block KIT/PDGFRA |
|||
Trial Type: |
Specifically GIST and only GIST |
|||
Other Protocol IDs: |
300383
2025-522229-37-00 ( EU Trial (CTIS) Number ) |
|||
Sponsor: |
GlaxoSmithKline |
|||
Patient Contact: |
US GSK Clinical Trials CallCenter
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com |
|||
Contact email: |
||||
Contact Phone: |
||||
Randomized: |
Randomized |
|||
IV or Oral: |
Oral |
|||
Trial Notes: |
Eligibility Criteria: Inclusion Criteria: Participants with histologically or cytologically confirmed GIST that is metastatic and/or surgically unresectable. Documented disease progression on or intolerance to imatinib administered for first-line treatment of unresectable/metastatic disease. Tumor tissue must be available to be submitted to the central laboratory for retrospective biomarker analysis. The sample may be from archival tissue or a new biopsy. Tissue samples are not required to be submitted centrally prior to randomization. |
|||
Trial Links |
Trial Results |
Trial Sites
Name |
Address |
City |
State |
Zip |
Country |
1505 Holcombe Blvd. |
Houston |
TX |
77030 |
USA |
|
Tacoma |
WA |
98405 |
USA |
||
Omaha |
NE |
68130 |
USA |